Marc Humbert
Overview
Explore the profile of Marc Humbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
877
Citations
37416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montani D, McLaughlin V, Gibbs J, Gomberg-Maitland M, Hoeper M, Preston I, et al.
Am J Respir Crit Care Med
. 2025 Mar;
PMID: 40035659
Objectives: To evaluate the effect of genetic variant status on sotatercept efficacy and effect of sotatercept treatment on biomarkers in pulmonary arterial hypertension Methods: PULSAR (NCT03496207) was a phase 2,...
2.
Rahaghi F, Humbert M, Hoeper M, White R, Frantz R, Hassoun P, et al.
Lancet Respir Med
. 2025 Feb;
PMID: 39987941
Novel treatments in pulmonary arterial hypertension (PAH) with significant pathophysiological and clinical responses have generated renewed interest in changing the course of the disease and achieving long-term disease control. Historically,...
3.
Robert F, Benchenouf F, Ha M, Cuomo A, Ottaviani M, Surbier M, et al.
JHEP Rep
. 2025 Feb;
7(3):101297.
PMID: 39980753
Background & Aims: Hepatopulmonary syndrome (HPS) results from portal hypertension, with or without cirrhosis, and is marked by pulmonary vascular dilations leading to severe hypoxemia. Although placental growth factor (PlGF)...
4.
Preston I, Badesch D, Ghofrani H, Gibbs J, Gomberg-Maitland M, Hoeper M, et al.
Eur Respir J
. 2025 Feb;
PMID: 39978862
Background: SOTERIA (NCT04796337) is an ongoing open-label study evaluating long-term safety, tolerability, and efficacy of sotatercept in participants with pulmonary arterial hypertension (PAH). Methods: Eligible adults with PAH on stable...
5.
Gerges C, Jevnikar M, Brenot P, Savale L, Beurnier A, Bouvaist H, et al.
Circ Cardiovasc Interv
. 2025 Feb;
18(2):e014785.
PMID: 39965044
Background: Riociguat and balloon pulmonary angioplasty (BPA) improve hemodynamics in inoperable chronic thromboembolic pulmonary hypertension. Importantly, comparative effects of riociguat and BPA on different components of right ventricular (RV) afterload...
6.
Thoreau B, Renaud A, Chafey P, Clary G, Le Gall M, Broussard C, et al.
Rheumatology (Oxford)
. 2025 Feb;
PMID: 39918970
Objectives: Pulmonary arterial hypertension (PAH) is a rare disease that may be associated with connective tissue diseases (CTD). Anti-fibroblast (AFA) and anti-endothelial cell autoantibodies (AECA) have been identified in idiopathic...
7.
Boucly A, Montani D, Bauer F, Artaud-Macari E, Bergot E, Boissin C, et al.
Eur Respir J
. 2025 Jan;
PMID: 39884763
Background: European guidelines recommend initial monotherapy in PAH patients with cardiovascular (CV) comorbidities based on the limited of evidence for combination therapy in this growing population. Methods: A retrospective analysis...
8.
Hoeper M, Gomberg-Maitland M, Badesch D, Gibbs J, Grunig E, Kopec G, et al.
Eur Respir J
. 2025 Jan;
PMID: 39884760
Introduction: Pulmonary arterial hypertension (PAH) is a progressive disease associated with significant morbidity and mortality. Sotatercept is a first-in-class activin signalling inhibitor that acts to restore the balance between the...
9.
Major K, Bosshard Taroni W, Fratangelo L, Humbert M, Lorusso G, DAmelio P
Rev Med Suisse
. 2025 Jan;
21(900-1):30-33.
PMID: 39812282
Neurocognitive disorders are a major public health challenge, affecting 55 million people, and are projected to triple by 2050. This year's research highlights pathological mechanisms such as mitochondrial dysfunction and...
10.
Jackson D, Heaney L, Humbert M, Kent B, Shavit A, Hiljemark L, et al.
Immunotherapy
. 2025 Jan;
16(20-22):1175-1184.
PMID: 39780731
No abstract available.